2591 related articles for article (PubMed ID: 26445347)
1. Metabolic reprogramming: the emerging concept and associated therapeutic strategies.
Yoshida GJ
J Exp Clin Cancer Res; 2015 Oct; 34():111. PubMed ID: 26445347
[TBL] [Abstract][Full Text] [Related]
2. Mitochondria and cancer chemoresistance.
Guerra F; Arbini AA; Moro L
Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.
Martinez-Outschoorn U; Sotgia F; Lisanti MP
Semin Oncol; 2014 Apr; 41(2):195-216. PubMed ID: 24787293
[TBL] [Abstract][Full Text] [Related]
4. [Even the Warburg effect can be oxidized: metabolic cooperation and tumor development].
Cordier-Bussat M; Thibert C; Sujobert P; Genestier L; Fontaine É; Billaud M
Med Sci (Paris); 2018; 34(8-9):701-708. PubMed ID: 30230466
[TBL] [Abstract][Full Text] [Related]
5. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies.
El Hassouni B; Granchi C; Vallés-Martí A; Supadmanaba IGP; Bononi G; Tuccinardi T; Funel N; Jimenez CR; Peters GJ; Giovannetti E; Minutolo F
Semin Cancer Biol; 2020 Feb; 60():238-248. PubMed ID: 31445217
[TBL] [Abstract][Full Text] [Related]
6. Linking metabolic reprogramming to therapy resistance in cancer.
Morandi A; Indraccolo S
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):1-6. PubMed ID: 28065746
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in Cancer Metabolism: New Concepts in an Old Field.
Gentric G; Mieulet V; Mechta-Grigoriou F
Antioxid Redox Signal; 2017 Mar; 26(9):462-485. PubMed ID: 27228792
[TBL] [Abstract][Full Text] [Related]
8. Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4.
Martinez-Outschoorn UE; Curry JM; Ko YH; Lin Z; Tuluc M; Cognetti D; Birbe RC; Pribitkin E; Bombonati A; Pestell RG; Howell A; Sotgia F; Lisanti MP
Cell Cycle; 2013 Aug; 12(16):2580-97. PubMed ID: 23860378
[TBL] [Abstract][Full Text] [Related]
9. Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities.
Ganapathy-Kanniappan S
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):212-220. PubMed ID: 28400131
[TBL] [Abstract][Full Text] [Related]
10. From Warburg effect to Reverse Warburg effect; the new horizons of anti-cancer therapy.
Benny S; Mishra R; Manojkumar MK; Aneesh TP
Med Hypotheses; 2020 Nov; 144():110216. PubMed ID: 33254523
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth.
Guido C; Whitaker-Menezes D; Lin Z; Pestell RG; Howell A; Zimmers TA; Casimiro MC; Aquila S; Ando' S; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Oncotarget; 2012 Aug; 3(8):798-810. PubMed ID: 22878233
[TBL] [Abstract][Full Text] [Related]
12. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression.
Vaupel P; Schmidberger H; Mayer A
Int J Radiat Biol; 2019 Jul; 95(7):912-919. PubMed ID: 30822194
[TBL] [Abstract][Full Text] [Related]
13. Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer.
Li C; Zhang G; Zhao L; Ma Z; Chen H
World J Surg Oncol; 2016 Jan; 14(1):15. PubMed ID: 26791262
[TBL] [Abstract][Full Text] [Related]
14. Tumoral microvesicle-activated glycometabolic reprogramming in fibroblasts promotes the progression of oral squamous cell carcinoma.
Jiang E; Xu Z; Wang M; Yan T; Huang C; Zhou X; Liu Q; Wang L; Chen Y; Wang H; Liu K; Shao Z; Shang Z
FASEB J; 2019 Apr; 33(4):5690-5703. PubMed ID: 30698991
[TBL] [Abstract][Full Text] [Related]
15. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment.
Martinez-Outschoorn UE; Pavlides S; Howell A; Pestell RG; Tanowitz HB; Sotgia F; Lisanti MP
Int J Biochem Cell Biol; 2011 Jul; 43(7):1045-51. PubMed ID: 21300172
[TBL] [Abstract][Full Text] [Related]
16. Targeting respiratory complex I to prevent the Warburg effect.
Vatrinet R; Iommarini L; Kurelac I; De Luise M; Gasparre G; Porcelli AM
Int J Biochem Cell Biol; 2015 Jun; 63():41-5. PubMed ID: 25668477
[TBL] [Abstract][Full Text] [Related]
17. Metabolic reprogramming of the tumour microenvironment.
Xing Y; Zhao S; Zhou BP; Mi J
FEBS J; 2015 Oct; 282(20):3892-8. PubMed ID: 26255648
[TBL] [Abstract][Full Text] [Related]
18. Emerging roles of Myc in stem cell biology and novel tumor therapies.
Yoshida GJ
J Exp Clin Cancer Res; 2018 Jul; 37(1):173. PubMed ID: 30053872
[TBL] [Abstract][Full Text] [Related]
19. Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication.
Suh DH; Kim HS; Kim B; Song YS
Biochem Pharmacol; 2014 Nov; 92(1):43-54. PubMed ID: 25168677
[TBL] [Abstract][Full Text] [Related]
20. [Metabolic reprogramming in cancer: the art of balance].
Yi M; Xiang B; Li X; Li G
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 38(11):1177-87. PubMed ID: 24316928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]